|
[Related PubMed/MEDLINE]
Total Number of Papers: 3447
|
|
|
| |
|
[Display Entries]
|
|
>> all entries
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2022 |
|
aOR, VREfm |
| 2 |
2022 |
|
PIM |
| 3 |
2022 |
|
--- |
| 4 |
2022 |
|
HP, ITT, RR, VPZ |
| 5 |
2022 |
|
--- |
| 6 |
2022 |
|
aOR, CIs |
| 7 |
2022 |
|
ACS, DAPT, GI |
| 8 |
2022 |
|
EE, EoE, PPI-nr-EoE, PPI-r-EoE |
| 9 |
2022 |
|
EndoFLIP, FLIP, POEM |
| 10 |
2022 |
|
CRC |
| 11 |
2022 |
A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis. |
CI, GERD, P-CAB, RR, TEAEs |
| 12 |
2022 |
A multicenter cohort analysis of fractures in histamine-2-receptor antagonist treated pediatric patients. |
H2RA, PHIS |
| 13 |
2022 |
A non-invasive combined strategy to improve the appropriateness of upper gastrointestinal endoscopy. |
PGI, UGIE |
| 14 |
2022 |
A Prescribing Cascade of Proton Pump Inhibitors Following Anticholinergic Medications in Older Adults With Dementia. |
ACB |
| 15 |
2022 |
A rare endoscopic pattern in a patient with gastroesophageal reflux disease. |
--- |
| 16 |
2022 |
A review on lactoferrin as a proton pump inhibitor. |
LF |
| 17 |
2022 |
Acid Suppression and Antibiotics Administered during Infancy Are Associated with Celiac Disease. |
CD, H2RAs, HR |
| 18 |
2022 |
Acute interstitial nephritis observed with three different triggering agents. |
AIN, AKI, NSAIDs |
| 19 |
2022 |
An extended 36-week oral esomeprazole improved long-term recurrent peptic ulcer bleeding in patients at high risk of rebleeding. |
--- |
| 20 |
2022 |
An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis. |
CIs, HRs, ICIs, OS, PFS |
| 21 |
2022 |
Analysis of Barrett's Esophagus and Its Risk Factors: A Cross-Sectional Study of 10,122 Subjects at a Japanese Health Examination Center. |
BE, NSAID, OR, RE |
| 22 |
2022 |
Analysis of effects of laryngopharyngeal reflux disease and proton pump inhibitor treatment on Eustachian tube function in patients with obstructive sleep apnea hypopnea. |
BMI, ETS-7, LPRD, OSA |
| 23 |
2022 |
Anticoagulant drugs with or without proton pump inhibitor and colorectal cancer risk: a population-based, case-control study. |
CRC, DOAC |
| 24 |
2022 |
Antireflux band mucosectomy: a novel minimally invasive approach for the treatment of refractory gastroesophageal reflux disease. |
ARBM, ARMS, TIF |
| 25 |
2022 |
Applying Lyon Consensus criteria in the work-up of patients with proton pump inhibitory-refractory heartburn. |
AET, GERD |
| 26 |
2022 |
Assessment of proton-pump inhibitor use at a tertiary teaching hospital in Nigeria. |
GITU, GOPD |
| 27 |
2022 |
Associated Mortality Risk of Proton Pump Inhibitor Therapy for the Prevention of Stress Ulceration in Intensive Care Unit Patients: A Systematic Review and Meta-analysis. |
CI, RCTs |
| 28 |
2022 |
Association between Benign Paroxysmal Positional Vertigo and Previous Proton Pump Inhibitor Use: A Nested Case-Control Study Using a National Health Screening Cohort. |
aOR, BPPV, CIs, ORs |
| 29 |
2022 |
Association between hospital-acquired pneumonia and proton pump inhibitor prophylaxis in patients treated with glucocorticoids: a retrospective cohort study based on 307,622 admissions in China. |
HAP |
| 30 |
2022 |
Association between Migraines and Prior Proton Pump Inhibitor Use: A Nested Case-Control Study Using a National Health Screening Cohort. |
--- |
| 31 |
2022 |
Association between Proton Pump Inhibitor Use and Risk of Hepatocellular Carcinoma: A Korean Nationally Representative Cohort Study. |
DDD, HCC |
| 32 |
2022 |
Association of Early Life Prescriptions for Antibiotics and Acid Suppressants with Childhood Psychotropic Prescriptions. |
aHR, H2RA |
| 33 |
2022 |
Association of Proton Pump Inhibitor and Infection and Major Adverse Clinical Events in Patients With ST-Elevation Myocardial Infarction: A Propensity Score Matching Analysis. |
MACE, PCI, STEMI |
| 34 |
2022 |
Autoimmune and immune-mediated inflammatory diseases after exposure to acid-suppressive medication: A systematic review and meta-analysis. |
H2RA, MC |
| 35 |
2022 |
Barriers to Guideline-Based Use of Proton Pump Inhibitors to Prevent Upper Gastrointestinal Bleeding. |
GI, PCPs |
| 36 |
2022 |
Bowel Habit Pattern of Patients with Self-Reported Constipation at Out Patient Department in North East Part of Bangladesh. |
--- |
| 37 |
2022 |
Chronic Proton-Pump Inhibitor Therapy and Fracture Risk in Women Aged Between 50 and 65 years: A Retrospective Case-Control Study. |
--- |
| 38 |
2022 |
Clinical efficacy of endoscopic antireflux mucosectomy vs. Stretta radiofrequency in the treatment of gastroesophageal reflux disease: a retrospective, single-center cohort study. |
ARMS, GEFV, GERD, GERD-HRQL, GerdQ, SRF |
| 39 |
2022 |
Clinical Endoscopic and Histologic Findings of a Long-Term Follow-Up (10.7 Years) After Roux-en-Y Laparoscopic Gastric Bypass: a Prospective Study. |
BE, BMI, GERD, LYGB |
| 40 |
2022 |
Clinical Formulation Bridging of Gefapixant, a P2X3-Receptor Antagonist, for the Treatment of Chronic Cough. |
--- |
| 41 |
2022 |
Clinical outcomes of asymptomatic low-grade esophagitis: results from a multicenter Chinese cohort. |
GERD |
| 42 |
2022 |
Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study. |
AEs, CI, HR, mCRC, ORR, OS, TTF |
| 43 |
2022 |
Clinical profile and characteristics of eosinophilic esophagitis patients presenting with refractory gastroesophageal reflux disease in Makassar, Indonesia. |
GERD |
| 44 |
2022 |
Clinical role of ambulatory reflux monitoring in PPI non-responders: recommendation statements. |
AET, GERD, RAM |
| 45 |
2022 |
Clinical trial: a controlled trial of baclofen add-on therapy in PPI-refractory gastro-oesophageal reflux symptoms. |
GERD, SAP |
| 46 |
2022 |
Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication. |
--- |
| 47 |
2022 |
Clinical Use of Lansoprazole and the Risk of Osteoporosis: A Nationwide Cohort Study. |
CIs, HRs |
| 48 |
2022 |
Clinical use of mean nocturnal baseline impedance and post-reflux swallow-induced peristaltic wave index for the diagnosis of gastro-esophageal reflux disease. |
GERD, MNBI, PSPWI |
| 49 |
2022 |
Clinical, histopathological features and efficacy of elimination diet and proton-pump inhibitor therapy in achieving histological remission in Asian children with eosinophilic gastritis. |
EG, FED, HPF |
| 50 |
2022 |
Clostridioides difficile infection in cancer patients receiving immune checkpoint inhibitors. |
CDI, ICIs, IMDC |
| 51 |
2022 |
Comparative Effectiveness of Various Eradication Regimens for Helicobacter Pylori Infection in the Northeastern Region of Poland. |
BQT, H. pylori, L-TT, M-TT |
| 52 |
2022 |
Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study. |
CI, H2RA, HR |
| 53 |
2022 |
Cost Analysis of Implementing an Exercise Program for Fall and Fracture Prevention in Older Adults on Proton Pump Inhibitor Therapy. |
--- |
| 54 |
2022 |
Cost-Effectiveness of Vonoprazan Compared With Proton Pump Inhibitors in Patients Taking Low-Dose Aspirin for Secondary Prevention of Cardiovascular Events in Japan. |
CV, GI, ICER, LDA, QALYs |
| 55 |
2022 |
Diagnostic thresholds and optimal collection protocol of salivary pepsin for gastroesophageal reflux disease. |
AM, GERD, PM |
| 56 |
2022 |
Direct-to-consumer strategies to promote deprescribing in primary care: a pilot study. |
--- |
| 57 |
2022 |
Do proton pump inhibitors increase the risk of dementia? A systematic review, meta-analysis and bias analysis. |
ROBINS-I, RRs |
| 58 |
2022 |
Dose-Dependent Proton Pump Inhibitor Exposure and Risk of Type 2 Diabetes: A Nationwide Nested Case-Control Study. |
cDDD, CI, OR, OR, T2DM, UGID |
| 59 |
2022 |
Drug treatment strategies for eosinophilic esophagitis in adults. |
EoE, STCs |
| 60 |
2022 |
Drug-Related Problems in Bariatric Surgery: a Retrospective Study. |
DRPs, NCC MERP, PFT |
| 61 |
2022 |
Effect of aluminum phosphate gel on prevention of early rebleeding after ligation of esophageal variceal hemorrhage. |
APG, EVB, EVL, PPI group |
| 62 |
2022 |
Effect of Proton Pump Inhibitor on the Outcome of Laryngeal Microsurgery in Patients With Vocal Fold Mucosal Disease With Reflux Symptoms. |
GRBAS, LMS, NHR, RSI, VF, VHI-10 |
| 63 |
2022 |
Effect of proton pump inhibitors on the clinical outcomes of PD-1/PD-L1 inhibitor in solid cancer patients. |
CI, HR, OS, PFS |
| 64 |
2022 |
Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacterpylori Infection (Hp-EuReg). |
HDDT |
| 65 |
2022 |
Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials. |
CI, H. pylori, RR, VPZ |
| 66 |
2022 |
Effectiveness of a multi-faceted intervention to deprescribe proton pump inhibitors in primary care: protocol for a population-based, pragmatic, cluster-randomized controlled trial. |
DDD, GPs |
| 67 |
2022 |
Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors. |
CI, HR, iPFS, IPTW, OR, OS, UC |
| 68 |
2022 |
Effectiveness of Proton-Pump Inhibitors in Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized Controlled Trials. |
CIs, COPD, MD, RCTs, RRs |
| 69 |
2022 |
Effects of CYP2C19 genetic polymorphisms on the cure rates of H. pylori in patients treated with the proton pump inhibitors: An updated meta-analysis. |
CYP2C19, EM, H. pylori, PM, PPIs, RCTs |
| 70 |
2022 |
Effects of prolonged proton pump inhibitor treatment on nutritional status and respiratory infection risk in cystic fibrosis: A matched cohort study. |
PA, pwCF |
| 71 |
2022 |
Effects of Proton Pump Inhibitors on Survival Outcomes in Patients with Metastatic or Unresectable Urothelial Carcinoma Treated with Pembrolizumab. |
CI, HR, ICIs, OS, PFS |
| 72 |
2022 |
Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. |
ICI, mRCC |
| 73 |
2022 |
Efficacy and safety of laparoscopic Roux-en-Y gastric bypass in symptomatic patients following fundoplication failure: a meta-analysis. |
BMI, GERD, LF, LRYGB, RLF |
| 74 |
2022 |
Efficacy of Endoscopic and Surgical Treatments for Gastroesophageal Reflux Disease: A Systematic Review and Network Meta-Analysis. |
CI, GERD, GERD-HRQL, LES, RR |
| 75 |
2022 |
Eighteen-year-old man with syncope with Helicobacter pylori as the culprit: a case report. |
GI, H. pylori, PUD |
| 76 |
2022 |
Empiric "Three-in-One" Bismuth Quadruple Therapy for Second-Line Helicobacter pylori Eradication: An Intervention Study in Southern Italy. |
BQT, CI, H. pylori, ITT, PP |
| 77 |
2022 |
Empiric treatment vs susceptibility-guided treatment for eradicating H. pylori: Is it possible to change that paradigm using modern molecular methods? |
H. pylori |
| 78 |
2022 |
Esophageal Microbiome in Healthy Children and Esophageal Eosinophilia. |
EE, EoE, RE |
| 79 |
2022 |
Esophagitis Dissecans Superficialis: A Frequently Missed and Rarely Reported Diagnosis. |
EDS |
| 80 |
2022 |
Establishing the Association Between Osteoporosis and Peptic Ulcer Disease: A Systematic Review. |
PMC, PUD, RCTs |
| 81 |
2022 |
Exposure to Proton Pump Inhibitors and the Risk of Incident Asthma in Patients with Coronary Artery Diseases: A Population-Based Cohort Study. |
CAD, CIs, H2RA, HRs |
| 82 |
2022 |
Factors associated with gastro-duodenal ulcer in compensated type 2 diabetic patients: a Romanian single-center study. |
--- |
| 83 |
2022 |
Factors related to delayed adverse events of endoscopic submucosal dissection in the duodenum. |
D-ESD |
| 84 |
2022 |
First-line therapies for H. pylori infection in Italy: a pooled-data analysis. |
--- |
| 85 |
2022 |
Fungal digestive enzymes promote macronutrient hydrolysis in the INFOGEST static in vitro simulation of digestion. |
GI, ONS |
| 86 |
2022 |
Gastric neuroendocrine tumor after prolonged use of proton pump inhibitor. |
NET |
| 87 |
2022 |
Gastrointestinal Bleeding Risk Factors in Patients with Type 2 Diabetes Mellitus. |
ASA, BMI, CHF, CKD, CVD, GIB, NOAC, NSAID |
| 88 |
2022 |
Health Care Cost Analysis of PPI or P-CAB-First Treatment in Patients With Gastroesophageal Reflux Disease. |
EPZ, GERD, P-CAB |
| 89 |
2022 |
High-dose proton pump inhibitors are associated with hospitalisation in bronchiectasis exacerbation. |
H2RA |
| 90 |
2022 |
Histamine 2 receptor antagonists do not improve the outcomes of hospitalized COVID-19 patients. |
H2RA |
| 91 |
2022 |
Impact of Acid Suppression Therapy on Renal and Survival Outcomes in Patients with Chronic Kidney Disease: A Taiwanese Nationwide Cohort Study. |
CKD, ESRD, H2RA |
| 92 |
2022 |
Impact of Helicobacter pylori Infection and Outcome of Anti-Helicobacter pylori Therapy in Patients with Reflux Laryngopharyngitis. |
HP, RFS, RLP, RSI |
| 93 |
2022 |
Impact of proton pump inhibitor management committee's multifaceted interventions on acid suppressant prescribing patterns in outpatient and emergency departments. |
--- |
| 94 |
2022 |
Impact of proton pump inhibitors on sustained virologic response in veterans treated with sofosbuvir/velpatasvir for chronic hepatitis C virus: A retrospective cohort study. |
HCV, SOF/VEL, SVR |
| 95 |
2022 |
Impact of proton-pump inhibitors on the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis. |
ICI, NSCLC, OS, PFS |
| 96 |
2022 |
Impact of Second-Generation Transoral Incisionless Fundoplication on atypical GERD symptoms: A Systematic Review and Meta-analysis. |
RSI, TIF |
| 97 |
2022 |
Impact of Stress Ulcer Prophylaxis Discontinuation Guidance in Mechanically Ventilated, Critically Ill Patients: A Pre-Post Cohort Study. |
H2RA, ICU, SUP |
| 98 |
2022 |
Inhibitory effect of roburic acid in combination with docetaxel on human prostate cancer cells. |
DOC, ESOM, ROB, siRNA |
| 99 |
2022 |
Interaction between xylanase and a proton pump inhibitor on broiler chicken performance and gut function. |
AX, AXOS, FCR, VFA |
| 100 |
2022 |
Intermittent Versus Continuous Infusion Dosing of Intravenous Proton Pump Inhibitors for Upper Gastrointestinal Bleeding. |
ICU, UGIB |
|
A Search Service for Abbreviation / Long Form
